Kornimate/medical-research-clean huggingface dataset:
the effects of wellness training given to fifth grade students during the covid-19 epidemic period

Conditions: Health Behavior

Summary: this study conducted an experimental study with a randomized control group to decide on the quality of life and physical activity of the wellness education for fifth grade students during the covid-19 pandemic process.

after the population and sample calculations were made, the students who had their pre-tests were randomized to the wellness education group and the control group. in this study conducted in two state secondary schools affiliated to kırşehir provincial directorate of national education, the experimental group was given wellness training. no intervention was made to the control group. four weeks after the training, the students were post-tested and the data were analyzed. in order not to affect the groups from the practices to be made, first of all, schools were randomized and the schools were divided into wellness education group and control group with a closed envelope lot method. prof. dr. erol güngör secondary school (group i) wellness education group has been assigned to kırşehir merkez yunus emre secondary school (group ii) control group. experimental and control groups in order to reduce selection bias and control variables that may have an effect on outcome variables; a randomized assignment was made by a statistician who did not know the names and characteristics of the students. in determining the students to be included in the study; student lists and the excel 2016 program were used, and simple random sampling was performed. the student lists assigned to the groups by the expert were submitted to the researcher before the initiatives started.

Eligibility criteria:
inclusion criteria: * being a fifth grade student, * not having any physical or mental disability, * agree to participate in research, * not allowed to participate in research by their parents. exclusion criteria: -

Keywords: wellness adolescent quality of life physical activity
randomized trial of home versus clinic-based screening for sexually transmitted infections

Conditions: Chlamydia; Gonorrhea

Summary: this study randomizes women using long-acting reversible methods of contraception to home-based std screening through the mail compared to screening available in a clinical setting. we hypothesize that women randomized to home-based screening will be more likely to complete screening.


Eligibility criteria:
inclusion criteria: * participant in contraceptive choice cohort study * using a long-acting reversible method of contraception * completed baseline clinical survey in the contraceptive choice cohort study exclusion criteria: * living outside the united states at time of annual sti screening
a study of milvexian in participants after a recent acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (mace) (the composite of cardiovascular \[cv\] death, myocardial infarction \[mi\], and ischemic stroke).


Eligibility criteria:
inclusion criteria: * participants must have an index event that meets all 3 of the following criteria within 7 days prior to randomization: a) clinical syndrome consistent with spontaneous cardiac ischemia, b) diagnosis of acute coronary syndrome (acs) (that is, st-elevation myocardial infarction \[stemi\], non-stemi, or unstable angina \[ua\]), c) cardiac biomarker elevation (example, troponin i, troponin t, creatine kinase-mb \[ck-mb\]) above the upper limit of normal as determined by the local laboratory * participants must have at least 2 of the following risk factors:a) age 65 or older, b) diabetes mellitus, c) history of a prior myocardial infarction (mi) (other than index acs event), d) multivessel coronary artery disease (cad), e) history of coronary artery bypass graft (cabg) surgery prior to index acs event, f) history of peripheral artery disease (pad) or cerebrovascular disease (example, carotid atherosclerosis, intracranial artery stenosis, g) conservative management (that is, no percutaneous intervention \[pci\] or cabg after index acs event), h) any one or more of the following high-risk angiographic features i) total stent length of greater than (\>) 30 millimeters (mm), ii) thrombotic target lesion, iii) bifurcation lesion treated with more than one stent, iv) calcified target lesion treated with atherectomy, v) treatment of obstructive left main or proximal left anterior descending artery for index acs (or clinical diagnosis of an anterior stemi) * all female participants of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin (hcg) or urine test at screening * a female participant must not be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half-lives) after the last dose of study intervention exclusion criteria: * mi secondary to ischemia due to either increased oxygen demand or decreased supply (type 2 mi) or periprocedural mi as the index acs event * planned cabg or staged pci after randomization * any condition that requires chronic anticoagulation at the discretion of the investigator and/or local guidelines * conditions with a significant increased risk of bleeding (example, clinically significant bleeding within previous 3 months, known bleeding diathesis, et cetera)
a randomized comparison of clinical outcomes between everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in long coronary lesions

Conditions: Coronary Artery Disease

Summary: pci of diffuse long coronary lesions still remains challenging because of relatively high risk of in-stent restenosis and stent thrombosis compared to short coronary lesions. the purpose of the study is to compare an incidence of composite of major adverse cardiovascular events (maces) at 1 year between absorb everolimus-eluting bvs and xience ees after coronary intervention in long lesions.


Eligibility criteria:
inclusion criteria: * age 19-85 years * patients with ischemic heart disease requiring pci * significant coronary de novo lesion (stenosis \>50% by quantitative angiographic analysis) requiring stent ≥28 mm in length based on angiographic estimation * reference vessel diameter of 2.5 to 3.75 mm by operator assessment exclusion criteria: * acute myocardial infarction within 48 hours with unstable hemodynamics requiring pharmacologic or mechanical support * complex coronary morphology including left main disease and bifurcation lesion requiring two-stent technique * contraindication or hypersensitivity to anti-platelet agents or contrast media * treated with any metallic stent or bvs within 3 months at other vessel * cardiogenic shock * left ventricular ejection fraction \<40% * pregnant women or women with potential childbearing * inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator * inability to understand or read the informed content

Keywords: bioresorbable vascular scaffold, drug eluting stent, coronary artery disease
surgical treatment of adrenal diseases- laparoscopic vs. robotic-assisted adrenalectomy

Conditions: Adrenal Tumor; Adrenal Disease; Adrenal Mass; Adrenalectomy; Status; Adrenal Hyperplasia; Adrenal Gland Metastasis; Adrenal Cortex Diseases; Pheochromocytoma; Cushing Syndrome; Conn Adenoma; Adrenocortical Carcinoma; Adrenocortical Adenoma; Adrenocortical Tumor

Summary: the goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases. the main question it aims to answer are: 1. to find the superiority of one the the surgical method mentioned above 2. to compare the quality of life in patients with adrenal mass before surgery and after laparoscopic or robotic-assisted adrenalectomy.


Eligibility criteria:
inclusion criteria: * indicated adrenalectomy based on endocrinological and imaging examination. * written consent to participate in the study. exclusion criteria: * simultaneous bilateral adrenalectomy. * adrenal expansion \> 12 cm. * suspected malignant adrenal tumor with infiltrative growth or tumor venous thrombus according to imaging examination.

Keywords: adrenal tumor pheochromocytoma conn adenoma cushing syndrome adrenalectomy laparoscopic surgery da vinci surgical system
myopia prevalence in canadian school children - a pilot study

Conditions: Myopia

Summary: the goal of this study is to determine the prevalence of nearsightedness in canadian school children living in the waterloo region.


Eligibility criteria:
inclusion criteria: * has had a parent/legal guardian read the study consent form and who agrees to allow them to participate in the study by signing the consent form * has had the "letter of assent for children" explained to them, the child has agreed to participate and the letter has been signed by the study investigator and the child * has provided the completed questionnaire (appendix 4a for parents to complete on behalf of their children in school grades 1 and 2, 6 and 7; appendix 4b for children to complete that are in school grades 11 and 12) * is currently in school grades 1 and 2, 6 and 7 or 11 and 12 * is willing and able to follow instructions and maintain the appointment schedule exclusion criteria: * has not given verbal assent to participate * has known sensitivity to the diagnostic pharmaceuticals to be used in the study * has undergone refractive error surgery or orthokeratology * has serious medical disorders or eye diseases/abnormalities such as amblyopia and cataract or a cognitive inability to conduct the tests
comparison of the effects of dexmedetomidine and lidocaine on blood pressure and heart rate response

Conditions: General Anesthesia

Summary: endotracheal intubation is considered a definitive therapy and the gold standard for airway management. however, this procedure carries several risks, including sudden increases in blood pressure and heart rate. these spikes in blood pressure and heart rate can be tolerated by healthy individuals, but for patients with cerebrovascular and cardiovascular risk factors, they can be extremely dangerous and even life-threatening. various techniques and drug choices can be employed to prevent the hemodynamic surges associated with endotracheal intubation, including the use of anesthetic drugs from the α2-adrenergic agonist and amide classes. one of the α2-adrenergic agonists commonly used to prevent hemodynamic surges during endotracheal intubation is dexmedetomidine, while one of the amide drugs frequently used for this purpose is lidocaine.

dexmedetomidine works very selectively on noradrenergic receptors distributed both within and outside the central nervous system, particularly in the pons and medulla. presynaptic stimulation of α2 receptors can reduce the release of norepinephrine and the activation of postsynaptic α2 receptors. lidocaine works by inhibiting sodium channels within cells, preventing the occurrence of action potentials and the transmission of impulses along nerves. lidocaine also acts by blocking calcium and potassium channels as well as n-methyl-d-aspartate (nmda) receptors.

Eligibility criteria:
inclusion criteria: * patients aged 18-59 years. * patients scheduled for oral intubation. * physical status asa i and ii (american society of anesthesiologists). * patients with mallampati classification i-ii. exclusion criteria: * history of allergy to the drugs that will be used. * pregnant patients. * patients taking medications that affect blood pressure and heart rate, such as vasodilators, adrenergic blockers, antiarrhythmics, and cardiac stimulants. * patients with arrhythmias, av block, liver disorders, hypertension, and hypoalbuminemia. * patients who have been given opioids within the last 24 hours. * patients with predicted intubation difficulties.

Keywords: haemodynamic response endotracheal intubation dexmedetomidine lidocaine
comparative study of mesh versus no mesh in prolapse surgery

Conditions: Vaginal Prolapse; Cystocele

Summary: hypothesis / aims of study a rct has shown that results of prolapse repair via vaginal approach could be improved when a polypropylene mesh is used as tissue support (1). however, non protected heavy-weight meshes were associated with a high rate of local complications such as vaginal erosions and dyspareunia (2). the aim of this multicentre study is to evaluate anatomical and functional results of an innovative low-weight polypropylene mesh protected by an absorbable hydrophilic film in the prolapse repair by vaginal route, in comparison by the standard anterior colporrhaphy. study design, materials and methods this study involves 15 centres in french private or public hospital. patients will be randomly allocated to be operated by a standard anterior colporrhaphy or by an anterior repair reinforced by a specially designed mesh: ugytextm (sofradim, france). ugytex is a low-weight (38g/m²) and highly porous (average porosity: 89%, pores over 1.5mm) polypropylene monofilament mesh offering tissue ingrowth and connective differentiation for a stable and long-term support. the mesh is coated with a hydrophilic film composed of atelocollagen, polyethylene glycol and glycerol. the absorbable coating protects delicate pelvic viscera from the risk of acute inflammation during the healing's inflammatory peak. prolapse severity will be evaluated using the pop-q system. in order to evaluate the patient's quality of life, the validated pfdi and the pfiq questionnaires will be used preoperatively and during follow-up (3), as well as a validated questionnaire on sexual problems. the difference on one-year cure rate should be 15% (80% for the anterior colporrhaphy and 95% for the mesh repair). then the estimated number of patient is 97 in each arm.


Eligibility criteria:
inclusion criteria: * patients older than 60 years-old * anterior vaginal wall prolapse of stage 2 or more (pop-q system) * symptomatic prolapse * informed consent signature obtained exclusion criteria: * patient not able to read french language * patient with a anterior prolapse of stage 1 * urinary of vaginal infection * hepatopathy with ascitis * diabetes uncontrolled * treatment by corticosteroids * previous pelvic irradiation * intraoperative bladder injury
chair-bound exergaming in pre-frail/ frail older adults in nursing home

Conditions: Frailty in Older Adults

Summary: this pilot randomized controlled trial is designed to investigate the effectiveness of chair-bound exergaming on improving physical and cognitive function in pre-frail/ frail nursing home residents

objective to explore the effects of the chair-bound exergaming on the enjoyment of physical activity in in pre-frail/ frail nursing home residents. to evaluate the effects of the chair-bound exergaming in improving physical and cognitive function in pre-frail/ frail nursing home residents. research plan and methodology thirty nursing home residents will be recruited from the nursing homes. all the eligible participant will be randomly allocated to either one of the following 2 groups (i) exergaming (intervention group), or (ii) wait list control. 1. intervention group (exergaming group, erg) those allocated to the erg will receive supervised chair-bound exercise programme for 12 weeks. 2. control group (wait list control, cg) those allocated to the cg will receive supervised chair-bound exercise programme for 12 weeks after post-assessment.

Eligibility criteria:
inclusion criteria: * older adults aged 60 years or older living in the nursing homes; * pre-frail or frail according to the fried frailty phenotypes; * ability to understand and execute instructions; and * ability to sit unassisted on a chair or in a wheelchair. exclusion criteria: * no controlled medical diagnosed of severe cardiometabolic, respiratory and musculoskeletal disorders; * any conditions that hinder the participation of intervention and assessment; and * being involved in any other clinical trials.
a study to evaluate the effect of ccx140-b on urinary albumin excretion in subjects with type 2 diabetes and albuminuria

Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the effect of treatment with ccx140-b on urinary albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to study the safety and efficacy of the medication in this patient population.

study acquired by amgen and all disclosures were done by previous sponsor chemocentryx.

Eligibility criteria:
key inclusion criteria: * aged 18-75 years inclusive, with documented previously diagnosed type 2 diabetes mellitus (per american diabetes association \[ada\] criteria), and treated with oral antidiabetic drugs * albumin:creatinine ratio (acr) of 200 to 3000 mg/g creatinine, inclusive, based on two values obtained from two first morning urine samples taken on two separate days during the screening period * estimated glomerular filtration rate based on serum creatinine (egfr, determined by modification of diet in renal disease \[mdrd\] equation) of ≥ 25 ml/min/1.73 m(2) * must be on a stable dose of an angiotensin-converting enzyme (ace) inhibitor or an angiotensin receptor blocker (arb) for at least 8 weeks prior to screening * fasting plasma glucose less than 270 mg/dl at screening key exclusion criteria: * type 1 diabetes mellitus or history of diabetic ketoacidosis * previous renal transplant or known non-diabetic renal disease, except related to hypertension * undergone renal dialysis at any time in the past * received chronic (more than 7 days continuously) systemic glucocorticoid or other immunosuppressive treatment within 8 weeks of screening * use of bardoxolone, atrasentan or other endothelin antagonist within 8 weeks of screening * received chronic (more than 7 days continuously) non-steroidal anti-inflammatory drug (nsaid) treatment within 2 weeks of screening * cardiac failure (class iii or iv), history of unstable angina, symptomatic coronary artery disease, myocardial infarction or stroke within 12 weeks of screening * poorly-controlled blood pressure (systolic blood pressure \>155 or diastolic blood pressure \>95, with blood pressure measured in the seated position after at least 5 minutes of rest)
impact of silicon-based formulations on wound healing of laser-induced microscopic skin lesions

Conditions: Wound Healing

Summary: delayed wound healing is considered a health problem with devastating consequences for patients, healthcare systems, and societies. over the past 20 years, many other groups, as well as ourselves, have evaluated various alternatives to improve wound healing. despite this, the scientific evidence demonstrating the efficacy of recently developed treatments is often limited. stratacel® and stratamed® are two gels approved by swissmedic and the fda for use in improving wound healing. to this end, the efficacy of these formulations has been visually tested by a physician or by patients. using the most advanced medical technologies (confocal microscopy and lcoct), this study aims to investigate the effect of these formulations on the healing of human skin. for this research, a total of 20 volunteers will be included in this study. volunteers will have up to 7 follow-up appointments over 21 days. each appointment will last approximately 30 minutes and will be used to perform external measurements of skin healing. all volunteers will use the same formulations (stratacel® and stratamed®) with the only difference between volunteers being the anatomical area of application of the formulation. this will be determined by chance. the active participation of the participant is requested for the application of the formulations on the skin twice a day during the trial.


Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers age ≥18 years to 50 years 2. subjects must be willing and able to participate as required by the protocol. 3. subjects must be willing and able to provide written informed consent. exclusion criteria: 1. evidence of any relevant skin or systemic disease (for example diabetes mellitus, cardiovascular disease, hypertension, chronic or acute skin disease) possibly affecting the wound healing of the test site. 2. any skin alteration (for example tattoo or scar) on the test site. 3. test sites with terminal hairs 4. pregnancy or breastfeeding. 5. history of hypertrophic scars or keloid formation or a similar abnormal wound healing. 6. intake of any drug which in the evaluation of the investigator may interfere with the interpretation of trial results or are known to cause clinically relevant interferences. 7. body mass index (bmi) \> 36 kg/m². 8. have any other condition (including drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol.
stress management and resilience training (smart) intervention for family caregivers of individuals with advanced cancer

Conditions: Family Caregivers; Advanced Cancer

Summary: this study examines stress management and resilience training (smart) for family caregivers (fcg) of patients receiving chemotherapy for advanced cancer to potentially help with the stressful aspects of providing care. all participants will receive the smart intervention.

fcgs experience stress and extensive demands in providing care for those with head and neck cancer. teaching the principles of mindfulness and compassion to fcgs has the potential to protect their psychological health and well-being. this may allow them to provide effective, compassionate care to patients, which ultimately puts the needs of the patient first. mindfulness interventions have demonstrated decreased stress and anxiety, and improved self-compassion for individuals, but entail numerous sessions over several weeks, a barrier for caregivers. the smart program, a brief mindfulness program, has demonstrated improvements in resilience, anxiety, perceived stress, and mindfulness for healthcare providers and patients.

Eligibility criteria:
inclusion criteria: * primary caregiver of patient with advanced head and neck cancer receiving chemotherapy, living with the patient at least 50% of the time during treatment, able to read and speak english, cognitively intact, able to take smart class within 2 weeks of enrollment exclusion criteria: * self-identified mental health diagnoses, less than 18 years of age, not living with patient at least 50% of the time, unable to read and speak english

Keywords: stress management resilience